Breaking News
Investing Pro 0
👀 Bezos, Buffett & Berkowitz: What's in Their Portfolios? Unlock Data

U.S. FDA approves Lexicon Pharma's drug for heart failure

Published May 26, 2023 04:31PM ET Updated May 26, 2023 05:25PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
 
LLY
-0.36%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LXRX
+9.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SNY
-0.15%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Khushi Mandowara

(Reuters) -The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals (NASDAQ:LXRX) Inc's drug for a broad treatment of heart failure, including in adult patients with type 2 diabetes, the company said on Friday.

Shares of the company rose 13% in extended trading.

The oral drug, sotagliflozin, is the company's first to be approved by the U.S. health agency and will be sold under the brand name Inpefa. It had previously failed to win U.S. approval as an add-on to insulin therapy for type 1 diabetes.

Sotagliflozin belongs to a class of medicine that helps regulate blood glucose levels and reduce the risk of weight gain by inhibiting SGLT1 and SGLT2 proteins.

Jardiance, a drug developed by Eli Lilly (NYSE:LLY) and Boehringer Ingelheim that belongs to the same class, has already been approved by the U.S. regulator for the same indication.

Lexicon, which plans to launch the drug by the end of June, said the medicine's wholesale price is expected to be on par with existing branded heart failure medications.

The current list price of Lilly's Jardiance, the drug's main competitor, is $570.48 for a month's supply.

Sotagliflozin presents a unique proposition in heart failure, especially considering the drug's differentiated benefit in hospitalized patients, compared with existing treatments, Piper Sandler analyst Yasmeen Rahimi said ahead of the approval.

Rahimi estimates the drug to rake in sales of $112 million by 2025 and about $576 million by 2028.

Lexicon partnered with French drugmaker Sanofi (NASDAQ:SNY) SA to develop the drug. However, Sanofi later parted ways with Lexicon after paying a $260 million termination fee.

The FDA approval was based on a late-stage study that showed the drug, when compared with a placebo, reduced the risk of cardiovascular death and hospitalization due to heart failure in adults with type 2 diabetes or certain other health conditions.

U.S. FDA approves Lexicon Pharma's drug for heart failure
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email